Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus
Status:
Terminated
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
A 4-month, randomized, prospective, open-label comparison trial of hydroxychloroquine vs.
pioglitazone in type 2 diabetic patients inadequately controlled on maximally tolerated doses
of metformin plus a sulfonylurea.